Steglatro (ertugliflozin) is a prescription drug that ‘s used for type 2 diabetes in adults. The drug comes as an oral tablet. It’s usually taken once per day. The active ingredient in Steglatro is ...

One of the fastest-growing classes of diabetes drugs now has a new contender: Steglatro, the SGLT2 drug from Merck & Co. and Pfizer. When it rolls out in January, the drug will have to tackle the ...

Steglatro, Steglujan, and Segluromet have all received FDA approval for the treatment of type 2 diabetes. Merck and Pfizer announced that the Food and Drug Administration (FDA) has approved Steglatro ...

A new sodium-glucose co-transporter 2 medication to treat type 2 diabetes is joining the field: the FDA approved ertugliflozin (Steglatro) from Merck and Pfizer as a single therapy and in combination ...

Merck Co., Inc. MRK and Pfizer PFE presented data from phase III VERTIS CV cardiovascular (“CV”) outcomes study on SGLT2 inhibitor, Steglatro (ertugliflozin), at the American Diabetes Association’s ...

(RTTNews) - Merck & Co. Inc. (MRK) and Pfizer Inc. (PFE) said that the U.S. Food and Drug Administration has approved Steglatro (ertugliflozin) tablets, an oral sodium-glucose cotransporter 2 or SGLT2 ...

Merck and Pfizer’s Steglatro, late to the SGLT2 party, has been working to catch up to its in-class rivals, which already bear heart-helping approvals. But its cardiovascular outcomes data won’t help ...

A Type 2 diabetes drug, developed by Merck & Co. and Pfizer, won FDA approval Dec. 19., according to Reuters. 1. The drug, Steglatro, is a SGLT2 inhibitor, which works by causing patients with Type 2 ...

(Reuters) - A new drug developed by Merck & Co and Pfizer Inc won U.S. approval on Wednesday to treat type II diabetes, the Food and Drug Administration said, adding another competitor to a growing ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The FDA approved three new medicines containing the ...